AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03073642 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydrotherapy
Description: Hydrotherapy sessions, lasting 45 minutes, twice a week for 12 weeks.
Study NCT03073642 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrotherapy
Description: Hydrotherapy sessions, lasting 45 minutes, twice a week for 12 weeks.
Study NCT03106740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline Hydrochloride 100mg Capsule
Description: Minocycline 100mg will be administered by mouth daily for 2 weeks
Study NCT03106740 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance-Positron Emission Tomography Imaging
Description: Up to 15 millicuries of \[11C\]PBR28 will be administered to each subject at each imaging visit, for a maximum of 2 imaging visits.
Study NCT03106740 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Magnetic Resonance-Positron Emission Tomography Imaging
Description: Up to 15 millicuries of \[11C\]PBR28 will be administered to each subject at each imaging visit, for a maximum of 2 imaging visits.
Study NCT03106740 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule
Description: 1 Placebo Capsule (compounded with lactose powder) will be administered by mouth daily for 2 weeks
Study NCT00463385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Study NCT00463385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Participants will take oral prednisone in the evening for 3 cycles of 28 days each (up to 84 days). The dose will be as follows: 1st cycle = 30 mg daily, 2nd cycle = 15 mg daily, 3rd cycle = 15 mg every other day.
Study NCT05054998 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/MRI
Study NCT00463385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to pomalidomide
Description: Matching pomalidomide placebo tablets
Study NCT00463385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to prednisone
Description: Matching prednisone placebo tablets
Study NCT04047459 — intervention group
Intervention type: OTHER
Intervention: Tissue samples collection and cells isolation
Description: During surgery, leftover samples of bone (femoral head/ trabecular bone tissue) and muscle will be collected. Then they will be sent to the laboratory where isolation of cells will be performed.
Study NCT00711165 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 puffs, qd
Study NCT00711165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate
Description: 400 mcg, qd for 8 weeks
Study NCT02333110 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: spatially fractionated radiation therapy
Description: A single dose of 15-20Gys of spatially fractionated radiation therapy
Study NCT03015168 — intervention group
Intervention type: RADIATION
Intervention: capecitabine and concurrent intensity modulated radiotherapy
Description: patients with rectal cancer undergoing capecitabine and concurrent intensity modulated radiotherapy
Study NCT02679716 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MRI of the cerebral arteries
Description: MRI of the cerebral arteries is performed
Study NCT00003726 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: lepirudin
Description: lepirudin
Study NCT01286896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Patients will start treatment with a continuous once-daily dose of 37.5 mg sunitinib. After 22 days the first dose modification will be performed based on the total trough levels (TTL) combined for sunitinib plus SU12662 as measured by dried blood spot (DBS) analyses taken at day 15 ± 1day. A second dose modification will be performed after 36 days (7 days after the first dose adjustment) based on the TTL taken at day 29 ± 1day. One treatment cycle is defined as 28 days.~After 8 weeks a third analyses for TTL will be performed without further consequences for sunitinib dosing. Patients will be evaluated by CT- or MRI-scans for the response to therapy at week 8, and thereafter every 12 weeks. One blood sample will be harvested for pharmacogenetic analyses.
Study NCT00594568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY450139
Description: Administered orally once daily
Study NCT00594568 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally once daily
Study NCT01152931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amodiaquine + Artesunate
Description: Intervention:the intervention in this group involves the use of standard antimalarial therapy for uncomplicated malaria based on WHO recommendation. artemisin based combination therapy will be used. amodiaquine will be administered via the oral route at a dose of 10mg/kg daily while artesunate will be administered orally at Artesunate 100mg stat, 50mg 8hrs later and 50mg bd x 3days
Study NCT01152931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amodiaquine + Artesunate
Description: Intervention:the intervention in this group involves the use of standard antimalarial therapy for uncomplicated malaria based on WHO recommendation. artemisinin based combination therapy will be used. amodiaquine will be administered via the oral route at a dose of 10mg/kg daily while artesunate will be administered orally at 100mg stat, 5omg 8hrs later and 50mg 12hrly for 3 days
Study NCT01152931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lumefantrine + Artemether
Description: Lumefantrine and artemether combination will be administered orally at a dose of 120/20mg daily for 3days
Study NCT01152931 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Artesunate + vitamin A
Description: Artesunate will be administered orally at a dose of 100mg stat then 50 mg 8hrs later and 50mg 12hrly for 3days. vitamin A will be administered orally at a dose of 2000IU daily for 3 days
Study NCT01152931 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Artesunate + vitamin E
Description: Artesunate will be administered orally at 100mg stat, then 50mg 8hrs after and 50mg 12hrly for 3 days. Vitamin E will be administered orally at 100mg dly for 3 days.
Study NCT01152931 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Artesunate + Zinc
Description: Artesunate will be administered orally at a dose of 100mg stat then 50mg 8hrs after and 50mg 12mg 12hrly for 3 days. Zinc gluconate will be administered orally at a dose of 50mg dly for 4 days
Study NCT01152931 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Artesunate + selenium
Description: Artesunate will be administered orally at 100mg stat and 8hrs later 50mg. then 50mg 12hrly for 3 days. selenium will be administered orally at a dose of 100ug dly for 4 days
Study NCT01152931 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amodiaquine + vitamin A
Description: Amodiaquine will be administered orally at a dose of 10mg/kg dly for 3days. Vitamin A will be administered orally dly at a dose of 2000IU for 4 days
Study NCT01152931 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amodiaquine + Vitamin E
Description: Amodiaquine will be administered orally at a dose of 10mg/kg dly for 3days. vitamin E will be administered orally at a dose 100mg daily for 4 days
Study NCT01152931 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amodiaquine + Zinc
Description: Amodiaquine will be administered orally at a dose of 10mg/kg dly for 3days. Zinc gluconate will be administered orally at a dose of 50mg dly for 4 days.
Study NCT01152931 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amodiaquine + Selenium
Description: Amodiaquine will be administered orally at a dose of 10mg/kg daily for 3days. Selenium will be administered orally at a dose of 100ug daily for 4 days if > 1year. 50ug daily for 4 days if \< 1 year.
Study NCT01152931 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Artesunate + vitamin A + vitamin E
Description: Tab Artesunate 50mg orally daily for 4 days. Vitamin A, 5000IU orally daily for 4days if \< 1 year. 10,000 IU orally daily for 4 days if > 1 year.
Study NCT01152931 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Artesunate + Vitamin A + Zinc
Description: Tab Artesunate 50 mg daily for 4 days. Vitamin A 5OOOIU daily for 4 days if \< 1 year. 10,000IU daily for 4 days if > 1 year. All administered orally.
Study NCT01152931 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Artesunate + Vitamin A + Selenium
Description: Tab Artesunate 50 mg orally, daily for 4 days. Vitamin A 5000IU orally daily for 4 days if \< 1 year. 10,000IU orally daily for 4 days if > 1 year.
Study NCT01152931 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Artesunate + Vitamin E + Selenium
Description: Tab Artesunate 50 mg orally daily for 4 days. Vitamin E 100 mg orally daily for 4 days. Tab selenium 100 ug orally daily for 4 days if > 1 year. 50 ug orally daily for 4 days if \< 1 year.
Study NCT01152931 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Artesunate + Vitamin E + Zinc
Description: Tab Artesunate administered orally at 50 mg daily for 4 days. Vitamin E 100 mg orally daily for 4 days. Tab Zinc 50 mg orally daily for 4 days if \< 1 year. 25 mg orally daily for 4 days if > 1 year.
Study NCT00319488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled Corticosteroid (Budesonide)
Description: Participants will receive inhaled corticosteroid for 7 days, at the first sign of RTI-associated symptoms.
Study NCT00319488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leukotriene Receptor Antagonist (Montelukast Sodium)
Description: Participants will receive leukotriene receptor antagonist for 7 days, at the first sign of RTI-associated symptoms.
Study NCT00319488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled Albuterol
Description: All participants will receive inhaled albuterol treatments four times a day.
Study NCT00319488 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled Albuterol
Description: All participants will receive inhaled albuterol treatments four times a day.
Study NCT01284413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1, Gemcitabine, Cisplatin
Description: S-1 is given daily for 7 consecutive days and gemcitabine and cisplatin are infused on day1. The cycle is repeated every 2 weeks.
Study NCT02793258 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: Subjects will receive 10 30-minutes sessions of two milliamps transcranial direct current stimulation , twice a day for 5 consecutive day.~Facial emotion recognition task and attentional task with measurement of eye-tracking, heartrate, respiratory frequency and skin conductance will be conducted before and after the first session, and after the last session.
Study NCT02793258 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: transcranial direct current stimulation
Description: Subjects will receive 10 30-minutes sessions of two milliamps transcranial direct current stimulation , twice a day for 5 consecutive day.~Facial emotion recognition task and attentional task with measurement of eye-tracking, heartrate, respiratory frequency and skin conductance will be conducted before and after the first session, and after the last session.
Study NCT03696420 — intervention group
Intervention type: OTHER
Intervention: Coordinates of active plots and VIM landmarks calculation
Description: Stimulation efficacy will be assessed by comparing, according to usual care, the clinical evaluation (FTM scale) with and without stimulation, and the four contacts of each electrode will be tested clinically, with an accelerometer and an electromyography to determine which one is the most active on tremor. Coordinates of the anatomical landmarks will be calculated on the pre-operative MRI and those of the active plots on the fusion between post-operative CT-scan and pre-operative MRI.
Study NCT01655784 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coil Embolization with larger Diameter Coils
Description: Eighteen Coils placed in cerebral aneurysm
Study NCT01655784 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coil Embolization with Standard Diameter Coils
Description: Cerebral aneurysms will be embolized with standard diameter coils.
Study NCT01074853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propranolol
Description: 10mg twice daily escalated to 80mg once daily
Study NCT01074853 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Matched placebo
Study NCT04650178 — intervention group
Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04650178 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaire
Study NCT02127788 — intervention group
Intervention type: DRUG
Intervention: Micafungin
Description: intravenous
Study NCT00276458 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: atorvastatin
Description: Atorvastatin 40mg tablet po qd (by mouth, once a day) for 6 weeks
Study NCT00276458 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Placebo
Description: Atorvastatin 20mg Pbo and ezetimibe 10mg Pbo tablets po qd (by mouth, once a day). for 6 weeks
Study NCT00276458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: ezetimibe
Description: Atorvastatin 20mg and ezetimibe 10mg tablets po qd (by mouth, once a day). for 6 weeks.
Study NCT00276458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo.
Description: Atorvastatin 40mg Pbo tablets po qd (by mouth, once a day). for 6 weeks.
Study NCT01111968 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pandemic vaccine 1
Description: 7,5µg of A/H1N1 with MPLA adjuvant - IB, suspension (5µg) + Al(OH)3
Study NCT01111968 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pandemic vaccine 2
Description: 3,75µg of A/H1N1 with MPLA adjuvant - IB, suspension (5µg) + Al(OH)3
Study NCT01111968 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pandemic vaccine 5
Description: 7,5µg of A/H1N1 with MPLA adjuvant - IB, emultion (5µg) + Al(OH)3 + Squalene 2% emulsion
Study NCT01111968 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pandemic vaccine 6
Description: 3,75µg of A/H1N1 with MPLA adjuvant - IB, emultion (5µg) + Al(OH)3 + Squalene 2% emultion
Study NCT01145846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine plus Daunorubicin [Arm II (AD regimen)]
Description: Cytarabine 200 mg/m2/day by continuous iv infusion over 24 hours daily for 7 days (D 1-7) plus Daunorubicin 90 mg/m2/day iv daily for 3 days (D 1-3)
Study NCT01111968 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pandemic vaccine 9
Description: 7,5 µg of A/H1N1 with Al(OH)3 + Squalene 2% emultion
Study NCT01111968 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pandemic vaccine 10
Description: 3,75 µg of A/H1N1 with Al(OH)3 + Squalene 2% emultion
Study NCT01111968 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pandmeic vaccine 11
Description: 7,5µg of A/H1N1 with Al(OH)3
Study NCT01111968 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pandmeic vaccine 12
Description: 3,75µg of A/H1N1 with Al(OH)3
Study NCT01111968 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pandmic vaccine 13
Description: 15µg of A/H1N1 with no adjuvant
Study NCT01111968 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo group 14
Description: All elements of the vaccine but antigen and adjuvant
Study NCT01907516 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cell phone-internet home glucose reporting system
Description: Glucose monitoring via cell phone and internet using the Confidant Diabetes Management Application and the Confidant Connector.
Study NCT01907516 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Cell phone-internet home glucose reporting system
Description: Glucose monitoring via cell phone and internet using the Confidant Diabetes Management Application and the Confidant Connector.
Study NCT01907516 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Voicemail home blood glucose reporting
Description: Glucose monitoring via standard telephone and fax reporting.
Study NCT01907516 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Voicemail home blood glucose reporting
Description: Glucose monitoring via standard telephone and fax reporting.
Study NCT02985476 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health reports
Description: Participants were sent 3 sets of individualised, educationally enriched health reports about their diagnosed inflammatory bowel disease history, care plan and updates on their recent health status, results or encounters with health care services.
Study NCT00828139 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ziv-aflibercept
Description: Given IV
Study NCT00828139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Description: Given IV
Study NCT00828139 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topotecan hydrochloride
Description: Given IV
Study NCT00518596 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic supplementation (Lactobacillus plantarum)
Description: GastroPlan capsules from a single lot will be used. The intervention consists of L. plantarum reconstituted in sterile 2.0 cc of 5% dextrose-saline, administered orally using an opaque-amber syringe.
Study NCT04614480 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Exome analysis
Description: Exome analysis of tumor DNA and constitutional DNA in patients included in 1st line treatment
Study NCT02774577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole body vibration training in vibrating platform in young
Study NCT02774577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole body vibration training in vibrating platform in elderly
Study NCT01572610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTA 402
Description: once a day, oral administration
Study NCT00934518 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation Therapy 60 Gy total dose in 30 fractions: 2.0 Gy/fraction once daily five fractions per week
Study NCT01853215 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T.A.L.O.N. Intraosseous System
Description: intraosseous catheter for use in the sternum
Study NCT00934518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Radiation Therapy 60 Gy total dose in 30 fractions: 2.0 Gy/fraction once daily five fractions per week~Cetuximab 400 mg/m2 of body surface area over a period of 120 minutes day 1 250 mg/m2 of body surface area over a period of 60 minutes weekly during radiation
Study NCT00794222 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile Tracking Young People's Experiences (mobiletype)
Description: A mobile phone self-monitoring program, based on momentary sampling techniques, that prompts young people to complete it four times a day. The program asks several questions about daily activities, mood, stress, eating and exercise.
Study NCT01542801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norfloxacin
Description: Norfloxacin 400 mg per day
Study NCT01542801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciprofloxacin
Description: Ciprofloxacin 750 mg per week
Study NCT00200863 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monochromatic visible light exposure
Description: Monochromatic light in the visible range from 420-620 nm up to 60uW/cm2 for 6.5 hours
Study NCT01485159 — intervention group
Intervention type: PROCEDURE
Intervention: Spirometry
Description: assessment of lung function by spirometry
Study NCT03154385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab (Mabthera ®) Belimumab (Benlysta ®)
Description: Rituximab (Mabthera ®): 1g IV at W0 and W2 Belimumab (Benlysta ®) : 10mg/kg IV, W0 + 2days, W2 + 2 days, W4, W8, W12
Study NCT04400058 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Octagam 10%
Description: Octagam 10%, 2 g/kg divided by 4 days (0.5 g/kg/day), administered by intravenous infusion over approximately 2 hours per day over 4 consecutive days
Study NCT04400058 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Placebo
Study NCT00837200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oncaspar, Doxil, Decadron
Description: Once enrolled, patients will receive a cycle (28 days) of Oncaspar (2500 IU/m2 IV on days 1, 15; Doxil 20 mg/m2 IV days 1,15; and Decadron 20 mg PO days 1, 8, 15, 22. Continue until disease progression or unacceptable side effects.